{
    "clinical_study": {
        "@rank": "35274", 
        "arm_group": [
            {
                "arm_group_label": "GDC-0199 + R-CHOP Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "GDC-0199 + G-CHOP Arm", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, open-label, dose-finding study of GDC-0199 administered orally in\n      combination with MabThera/Rituxan (R) or obinutuzumab (G) and standard doses of\n      cyclophosphamide, doxorubicin, vincristine and oral prednisone (CHOP) in patients with\n      Non-Hodgkins Lymphoma (NHL). Patients will be randomized to one of two treatment arms of\n      GDC-0199 in combination with R-CHOP and G-CHOP. The study will consist of two stages, a\n      dose-finding stage and an expansion stage. The maximum tolerated dose (MTD) of GDC-0199 in\n      combination with R-CHOP and G-CHOP will be determined during the dose-finding stage."
        }, 
        "brief_title": "A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        General Inclusion Criteria:\n\n          -  Patients, age > = 18 years\n\n          -  At least one bi-dimensionally measurable lesion defined as > 1.5 cm in its longest\n             dimension\n\n          -  Ability and willingness to comply with the study protocol procedures\n\n          -  Confirmed availability of archival or freshly biopsied tumor tissue prior to study\n             enrollment\n\n          -  ECOG performance status of 0, 1 or 2\n\n          -  Adequate hematologic function\n\n          -  For female patients of childbearing potential, agreement to use highly effective\n             forms of contraception\n\n        Dose Escalation Portion of the Study:\n\n          -  Patients must have histologically confirmed B-cell non-Hodgkin's Lymphoma (NHL)\n\n          -  Patients must have never received previous R-CHOP treatment\n\n          -  Any relapsed/refractory patients that are enrolled during the dose escalation should\n             have received only a single previous treatment regimen\n\n        Expansion Portion of the Study:\n\n          -  Patients must have previously-untreated diffuse large, B-cell lymphoma\n\n          -  International prognostic index (IP) score must be 2-5\n\n        Exclusion Criteria:\n\n        General Exclusion Criteria:\n\n          -  Contraindication to receive any of the individual components of CHOP, rituximab or\n             obinutuzumab\n\n          -  Primary CNS lymphoma\n\n          -  Vaccination with live vaccines within 28 days prior to randomization\n\n          -  History of other malignancy that could affect compliance with the protocol or\n             interpretation of results\n\n          -  Evidence of significant, concomitant disease or illness\n\n          -  Use of CYP3A inhibitors or inducers within 7 days of the first dose of GDC-0199\n\n          -  Requires use of Warfarin\n\n          -  Recent major surgery\n\n          -  Women must not be pregnant or breastfeeding\n\n        Dose Escalation Portion of the Study:\n\n          -  Prior anthracycline therapy\n\n          -  Chemotherapy or other investigational therapy within 5 half-lives of a biologic agent\n             with minimum of 28 days prior to the start of Cycle 1\n\n          -  Histologically confirmed mantle cell lymphoma (MCL) or small lymphocytic lymphoma\n             (SLL)\n\n        Expansion Portion of the Study:\n\n          -  Patients with transformed lymphoma\n\n          -  Prior therapy for non-Hodgkins Lymphoma (NHL)\n\n          -  Current Grade > 1 peripheral neuropathy\n\n          -  Ongoing therapy with calcium channel entry blocker drugs or therapy within 30 days of\n             C1D1\n\n          -  Prior radiotherapy to the mediastinal/pericardial region"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "248", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055820", 
            "org_study_id": "GO27878"
        }, 
        "intervention": [
            {
                "arm_group_label": "GDC-0199 + G-CHOP Arm", 
                "description": "Obinutuzumab 1000 mg on Days 1, 8, 15, Cycle 1. Following cycles on Day 1.", 
                "intervention_name": "obinutuzumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "GDC-0199 + R-CHOP Arm", 
                    "GDC-0199 + G-CHOP Arm"
                ], 
                "description": "Standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone (CHOP)", 
                "intervention_name": "CHOP", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "GDC-0199 + R-CHOP Arm", 
                    "GDC-0199 + G-CHOP Arm"
                ], 
                "description": "Daily doses of GDC-0199", 
                "intervention_name": "GDC-0199", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "GDC-0199 + R-CHOP Arm", 
                "description": "Rituximab 375 mg/m2 on Day 1 of every cycle", 
                "intervention_name": "rituximab [MabThera/Rituxan]", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Rituximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14618"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3002"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3050"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre Benite", 
                        "country": "France", 
                        "zip": "69495"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76038"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1081 HV"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3015 CE"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 EA"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada", 
                "France", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase Ib, Open-Label Study Evaluating The Safety And Pharmacokinetics Of GDC-0199 (ABT-199) In Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (Chop) In Patients With B-Cell Non-Hodgkins Lymphoma (NHL) and DLBCL", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO27878 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Incidence of dose-limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 9 months"
            }, 
            {
                "measure": "Complete response (CR) defined by PET/CT scan and bone marrow examination", 
                "safety_issue": "No", 
                "time_frame": "Approximately 9 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055820"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Relative dose intensity", 
                "safety_issue": "No", 
                "time_frame": "Approximately 9 months"
            }, 
            {
                "measure": "Objective response (partial or complete response) rate", 
                "safety_issue": "No", 
                "time_frame": "Approximately 9 months"
            }, 
            {
                "measure": "Response duration, defined as time from first documented response until relapse or death.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 year"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "CR defined by CT scan and bone marrow examination", 
                "safety_issue": "No", 
                "time_frame": "Approximately 9 months"
            }, 
            {
                "measure": "Pharmacokinetics: plasma concentration-time profile of GDC-0199", 
                "safety_issue": "No", 
                "time_frame": "Approximately 9 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}